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Abstract
The release of the neurotransmitter norepinephrine (NE) is modulated by presynaptic adenosine receptors. In the present
study we investigated the effect of a partial activation of this feedback mechanism. We hypothesized that partial agonism
would have differential effects on NE release in isolated hearts as well as on heart rate in vivo depending on the genetic
background and baseline sympathetic activity. In isolated perfused hearts of Wistar and Spontaneously Hypertensive Rats
(SHR), NE release was induced by electrical stimulation under control conditions (S1), and with capadenoson 6 ? 10
28 M
(30 mg/l), 6 ? 10
27 M (300 mg/l) or 2-chloro-N
6-cyclopentyladenosine (CCPA) 10
26 M (S2). Under control conditions (S1), NE
release was significantly higher in SHR hearts compared to Wistar (766+/287 pmol/g vs. 173+/218 pmol/g, p,0.01).
Capadenoson led to a concentration-dependent decrease of the stimulation–induced NE release in SHR (S2/S1=0.9060.08
with capadenoson 6 ? 10
28 M, 0.5460.02 with 6 ? 10
27 M), but not in Wistar hearts (S2/S1=1.0560.12 with 6 ? 10
28 M,
1.0360.09 with 6 ? 10
27 M). CCPA reduced NE release to a similar degree in hearts from both strains. In vivo capadenoson
did not alter resting heart rate in Wistar rats or SHR. Restraint stress induced a significantly greater increase of heart rate in
SHR than in Wistar rats. Capadenoson blunted this stress-induced tachycardia by 45% in SHR, but not in Wistar rats. Using a
[
35S]GTPcS assay we demonstrated that capadenoson is a partial agonist compared to the full agonist CCPA (74+/22% A1-
receptor stimulation). These results suggest that partial adenosine A1-agonism dampens stress-induced tachycardia
selectively in rats susceptible to strong increases in sympathetic activity, most likely due to a presynaptic attenuation of NE
release.
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Introduction
Sympathetic activity regulates heart rate and cardiac function
via stimulation of a wide variety of G-protein coupled receptors,
such as alpha- and beta-adrenergic receptors [1]. The only class of
drugs to date to be widely used to modulate the activity of the
sympathetic nervous system are beta blockers, mostly b1-selective,
which act by postsynaptic blockade of beta-adrenoceptors in the
heart. They do not influence presynaptic regulation of sympathetic
activity and the release of the neurotransmitter norepinephrine
(NE) [2,3].
A different way of modulating sympathetic activity is the
modulation of the release of NE from pre- or postganglionic nerve
terminals. Moxonidine, for example, is thought to attenuate
central sympathetic tone either by stimulating central I1-
imidazoline receptors in the medulla oblongata [4,5,6], or via
central presynaptic alpha-adrenoceptors [7], thereby reducing
sympathetic tone in the central nervous system. Clonidine, a
central a2-receptor agonist, also inhibits sympathetic tone by
peripheral presynaptic inhibition of transmitter release from
postganglionic neurons [8]. In the heart, NE is released from
sympathetic nerve terminals upon stimulation and acts on the
myocardium by modulating heart rate, myocardial contractility
and calcium handling via alpha- and beta-adrenergic receptors
[9]. Its exocytotic release is presynaptically modulated during
myocardial ischemia via adenosine-A1 and adrenergic a2-receptors
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18048[10,11]. Recently, agonists of the adenosine A1 receptor, either full
or partial, have been tested in a variety of disease conditions [12].
Because of the potential modulation of NE release in the heart,
agonists of the adenosine A1 receptor might offer a unique
opportunity to selectively modulate sympathetic activity to the
heart. In a recent phase-II study in patients with angina pectoris it
was noted that the novel A1-agonist capadenoson (BAY 68-4986)
selectively blunted the heart rate increase during treadmill exercise
without altering baseline frequency [12,13].
This effect of capadenoson on the heart rate could be due to a
presynaptic modulation of the release of NE which is particularly
effective under conditions of an increased sympathetic nerve
activity. To test this hypothesis, the effects of the adenosine-A1
agonist capadenoson on the NE release in vitro as well as on heart
rate in vivo was evaluated in two rat strains with genetically
different levels of sympathetic activity, Wistar and Spontaneously
Hypertensive rats (SHR). The latter strain has an increased
sympathetic tone already at rest and exhibits a much stronger
increase in sympathetic tone upon restraint stress than Wistar rats
[14,15].
Methods
Study drug
Capadenoson (molecular weight 520.0 g/mol) was provided by
Bayer Schering Pharma AG (Wuppertal, Germany) as a research
compound Bay 68-4986-EXTRUDAT Fa.20 Pt.041027 [16].
This water-soluble formulation contains 5% active substance by
weight. For the in vitro experiments the substance was solubilised in
dimethyl sulfoxide (DMSO) 10%, polyethylene glycol 30%, and
physiologic (0.9%) sodium chloride 60% (all Sigma-Aldrich,
Germany). The final concentration of DMSO in the perfusate
did not exceed 0.01%. For the in vivo experiments Bay 68-4986-
EXTRUDAT was weighed according to body weight and
administered orally. A dose of 0.15 mg/kg was chosen on the
basis of previous experiments which showed it not to induce
bradycardia in Wistar rats. The formulation was prepared freshly
each day before administration.
Stimulation-induced norepinephrine release
All animal experiments were conducted according to the Guide
for the Care and Use of Laboratory Animals (NIH publication
No. 86-23, revised 1985), and were approved by the Regierung
von Oberbayern (Az 55.2-1-54-2531.3-15-07).
A total of 14 Wistar rats and 18 SHR (Charles River Inc.,
Germany; body weight 200–50 g, all female) underwent experi-
ments to evaluate the exocytotic, stimulation-induced NE release
during electrical field stimulation as described before [11]. Rats
were killed by an injection of pentobarbital i.p. (0.5 ml/100 mg
body weight, Merial, Germany), and hearts were rapidly excised,
and placed in ice cold Krebs-Henseleit solution (KHL). They were
quickly mounted on a Langendorff apparatus for retrograde
perfusion with KHL. Perfusion rate was kept constant at 10 ml/
min, the temperature was adjusted to 37uC, and the pH to 7.4
through bubbling with 5% CO2/95% O2. Via an inflow line
desipramine (Sigma-Aldrich, Germany) at a concentration of
10
27 M was added to the perfusion buffer. After an equilibration
period of 20 minutes, electrical field stimulation was commenced
via two metal paddles adjacent to both sides of the beating heart
for 1 minute (5V, 6 Hz). We collected the efflux in plastic tubes the
minute before, during, and 3 minutes after the stimulation. These
were rapidly frozen in liquid nitrogen and stored at 220uC till
analysis. The NE release was calculated as the cumulative release
induced by the electrical stimulation. After the first stimulation
(S1), the study drug capadenoson at concentrations of 30 mg/l (6 ?
10
28 M) or 300 mg/l (6 ? 10
27 M), or 2-chloro-N
6-cyclopentyla-
denosine (CCPA, 10
26 M, Sigma-Aldrich), respectively, were
added via separate perfusion lines for 30 minutes. After this time a
second stimulation (S2) was executed to determine the effect of the
drugs on NE release compared to the first stimulation. The effect
of each pharmacological intervention was analysed by calculating
the ratio of NE release induced by the second and first stimulation
(S2/S1 ratio).
Determination of norepinephrine concentration
Norepinephrine was detected in the samples using high-
performance liquid chromatography (HPLC) with electrochemical
detection (ECD) [17]. After thawing samples were prepared by a
reagent kit for ‘‘catecholamines in plasma’’ (Chromsystems,
Germany). Shortly, 1 ml of the sample was mixed with 500 ml
extraction buffer plus 50 ml internal standard (IS), and extracted
by solid phase extraction (SPE). Elution from SPE column was
carried out by 120 ml elution buffer. Fifty ml of the eluted sample
were separated by HPLC. Epinephrine and norepinephrine were
detected by ECD, and quantified by an external standard
involving the IS. The sensitivity of this assay is ,15 pg/ml
norepinephrine. Values are given as pmol per g wet heart weight.
Restraint stress experiments and in-vivo telemetry
The in vivo experiments were approved by Landesamt
fu ¨r Natur, Umwelt und Verbraucherschutz (Az 8.87-
50.10.44.08.068). Female Wistar rats (n=24) or SHR (n=40) at
a body weight of 200–220 g (breeder: Charles River, Germany)
were included for a restraint stress test [18]. All animals were
housed at an ambient temperature of ,22uC, maintained on a 12-
hour light/dark cycle with free access to standard laboratory rat
chow and water ad libitum.
Animals were equipped with implantable radiotelemetry, and a
data acquisition system (Data Sciences International, St. Paul MN,
U.S.A.), comprised of a chronically implantable transducer/
transmitter unit equipped with a fluid-filled catheter. Rats were
instrumented at least one month prior to the experiments. The
transmitter was implanted into the peritoneal cavity and the
sensing catheter was inserted into the descending aorta. The
animals were allocated to 4 groups:
1) Wistar rats with vehicle or 2) capadenoson 0.15 mg/kg (each
n=12)
3) Hypertensive SHR with vehicle or 4) capadenoson 0.15 mg/
kg (each n=20)
All animals were treated with vehicle or capadenoson for 5 days.
Drug administration took place at 9.00 a.m. On day 5, all animals
were placed into transparent restraint tubes for a period of 2 hr
between 11:00 and 13:00. All animals experienced this treatment
for the first time in their life. A dose of 0.15 mg/kg was chosen
after prior dose-finding studies, which ruled out significant effects
of capadenoson on blood pressure between 0.1 mg/kg and
0.3 mg/kg, whereas there was a significant reduction in resting
blood pressure at higher doses (Fig. S1).
[
35S]-GTPcS binding assay
Human frontal cortex was obtained from Analytical Biological
Services Inc. (Wilmington, DE, USA). Membranes from the
human cortex were prepared as described previously [19].
[
35S]GTPcS binding was measured as described by Lorenzen
[20]. Briefly, 5 mg of membrane protein was incubated in a total
volume of 160 ml for 2 hr at 25uC in a shaking water bath.
[
35S]GTPcS binding in control incubations and in the presence of
capadenoson showed a linear time course up to this incubation
Adenosine A1 Agonism in Cardiac Sympathetic System
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triethanolamine, 1 mM EDTA, 5 mM MgCI2,1 0 mM GDP,
1 mM dithiothreitol, 100 mM NaCl, 0.2 units/ml adenosine
deaminase, 0.2 nM [
35S]GTPcS, and 0.5% bovine serum
albumin. Non-specific binding was determined in the presence
of 10 mM GTPcS. Incubations were terminated through filtration
of the samples over multiscreen FB glass fiber filters (Millipore,
Billerica, MA, USA) followed by two washes with binding buffer.
The filters were dried, coated with scintillator and counted for
radioactivity. Binding curves of [
35S]GTPcS were analyzed by
nonlinear regression using GraphPad Prism (GraphPad Software
Inc., San Diego, CA, USA).
GTP shift assay
Preparation of brain membrane: Crude synaptosomal mem-
branes from rat brain were prepared according to the method
described by Lohse [21]. Male Wistar rats (150–250 g) were killed
be cervical dislocation, the brain cortex was quickly removed and
immediately placed in 0.32 mol/l sucrose (4uC). The tissue was
homogenized in 10 volumes sucrose in a glass/teflon homogenizer
(clearing 0.2 mm; 500 rpm for 30 s). The homogenate was
centrifuged at 1000 x g for 10 min to remove the nuclear fraction
and the supernatant centrifuged at 30000 x g for 30 min to give
the P2 fraction. The pellets were resuspended in 10 ml of water
and left on ice for 30 min to give synaptosomal membranes. After
a final centrifugation step at 48000 x g for 10 min the membranes
were resuspended in 50 mmol/l Tris-HCl buffer, pH 7.4 and
incubated with 2 U/ml adenosine deaminase (ADA) at 37uC for
30 min. The membranes were frozen in small aliquots and stored
at 280uC until binding assay. Protein was measured according to
Bradford, using a BIOrad assay kit.
Receptor binding studies: The adenosine A1 receptor binding
assay was carried out on rat brain cortical membranes and with
0.4 nM [
3H] 8-cyclopentyl-1,3-dipropylxanthine (DPCPX,
Kd=0.28 nM) as the radioligand. The assay was performed as
originally described by Lohse et al. [22] and modified by van der
Wenden et al. [23]. 10 mg of membrane protein were incubated at
37uC for 20 min with 0.4 nM [
3H]DPCPX and adenosine A1
agonist in different concentrations in buffer (50 mM Tris-HCl,
pH 7.4, 2 U/ml ADA) in the presence and absence of GTP.
Nonspecific binding was determined in the presence of 10 mMR -
PIA. Incubation was terminated by rapid filtration through GF/B
glass fibre filter plates. Filters were washed three times with icecold
Tris-HCl buffer 50 mM, pH 7.4. Radioactivity of the filter plate
was counted with 100 ml scintillation cocktail in a Microbeta
TriLux beta counter (PerkinElmer, Massachusetts, USA).
Statistical analysis
All values are expressed as mean +/2 standard error of means,
unless otherwise indicated. Means were compared with ANOVA,
unless a nonparametric distribution was assumed. In this case
Kruskal-Wallis-test was performed. For the comparison of
norepinephrine values from second to first stimulation a paired
t-test was used. A p-value ,0.05 was considered statistically
significant.
Results
Effect of capadenoson on stimulation-induced NE release
The effect of capadenoson on stimulation-induced NE release
was evaluated in isolated perfused rat hearts of Wistar and SHR
strains.
Under basal conditions without pharmacological modulation of
A1 receptors, the NE release was 4-times higher in SHR compared
to Wistar rats (SHR 766+/287 pmol/g, n=18, vs. 173+/
218 pmol/g, n=14; p,0.01, fig. 1A). There was no indication
for depletion of norepinephrine under control conditions without
pharmacological intervention (Fig. S2).
As demonstrated in Fig. 1B, capadenoson had no effect on NE
release in Wistar rats, whereas addition of CCPA at a concentration
of10
26 Mledtoa robust decreaseintheamountofNErelease(S2/
S1=1.1+/20.11 for capadenoson 6 ? 10
28 M, n=6, p=0.9; S2/
S1=1.0+/20.09 for capadenoson 6 ? 10
27 M, n=4, p=0.8; S2/
S1=0.5+/20.02 for CCPA 10
26 M, n=4, p=0.007).
To the contrary, in SHR, capadenoson led to a significant
concentration-dependent decrease of NE, as shown in Fig 1C.
(S2/S1=0.9+/20.07 for capadenoson 6 ? 10
28 M, n=6, p=0.1;
S2/S1=0.6+/20.05 for capadenoson 6 ? 10
27 M, n=5, p=0.03;
S2/S1=0.5+/20.05 for CCPA 10
26 M, n=7, p=0.003).
Thus, we observed a reduction of stimulation-induced NE
release by capadenoson at a dose of 6 ? 10
27 M in SHR only. This
reduction was comparable to the effect of 10
26 M CCPA.
Effect of capadenoson on stress-induced increase of
heart rate
In the in vivo experiments, Wistar rats and SHR were pre-treated
with capadenoson at a concentration of 0.15 mg/kg for 5 days.
On day 5, a stress test (physical restraint) was performed for
2 hours. The plasma concentration of capadenoson measured
3 hours after drug intake remained constant in the 5 days prior to
the restraint stress test and averaged 7.63 mg/l on day 4 and 5,
respectively.
As listed in Table 1, mean heart rate was not affected by
capadenoson during resting condition, neither in Wistar nor in
SHR. During the 2 hours of physical restraint, we observed an
increased heart rate in both strains (Wistar and SHR), which
remained elevated throughout the restraint period (Fig. 2). After
release from restraint, the rats recovered slowly, and heart rate fell
to normal levels within 24 hours. As can be seen in Figure 2 and
Table 1, in Wistar rats there was no difference in the increase in
heart rate between animals treated with vehicle and animals
treated with capadenoson at a dose of 0.15 mg/kg (relative
increase in heart rate during stress: 18+/23% in vehicle-treated
animals, 15+/22% in capadenoson-treated animals). In contrast,
in SHR we observed a profound blunting of the stress-induced
heart rate increase compared to vehicle-treated animals (relative
increase in heart rate during stress: 36+/24% in vehicle-treated
animals, 20+/24% in capadenoson treated animals; p,0.05).
During stress, MAP increased in all groups, without any
statistical difference between animals treated with vehicle or
capadenoson, either in SHR or in Wistar (Fig. 2 and Table 1).
However, there was a tendency towards a smaller increase of
blood pressure during stress in SHR treated with capadenoson. In
SHR, blood pressure was already elevated before the stress
experiment, as expected in these animals.
Determination of partial adenosine-A1 agonism of
capadenoson
Capadenoson is known to be a selective agonist of adenosine-A1
receptors [16]. To study the binding efficacy of capadenoson to A1
adenosine receptors, we measured ligand dependent G protein
activation by binding of [
35S]GTPcS to membranes of human
brain cortex. CCPA, a well described full agonist of A1 adenosine
receptors, was used as control to determine maximal [
35S]GTPcS
binding. As shown in Fig. 3A, capadenoson stimulated
[
35S]GTPcS binding only to 7462% of the full effect of CCPA,
suggesting partial agonism.
Adenosine A1 Agonism in Cardiac Sympathetic System
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noson, GTP shift assays were performed with the standard full A1-
agonist CCPA and the A1-antagonist 8-cyclopentyl-1,3-dipropyl-
xanthine (DPCPX). CCPA showed a Ki value of 4.2 nM in the
binding assay on rat cortical brain membranes (Fig. 3D). In the
presence of 1 mM GTP this Ki value shifted to a value of 64 nM.
Therefore the GTP shift for CCPA is 15. DPCPX showed a GTP
shift of 1 with virtually identical Ki values in the absence and
presence of GTP (Fig. 3B). Capadenson showed a Ki value of
24 nM in the binding assay. In the presence of 1 mM GTP this Ki
value shifted to a value of 116 nM resulting in a GTP shift of 5 for
Capadenoson (Fig. 3C). Therefore capadenoson could be
demonstrated to be a partial agonist at the adenosine A1 receptor.
Discussion
In the present study we could demonstrate that the partial
adenosine A1-receptor agonist capadenoson leads to a profound
reduction of stimulation-induced NE release in vitro as well as to
blunted restraint stress-induced tachycardia in SHR, but not in
Wistar rats. In a recent phase-II study of the same compound it
was noted, that capadenoson specifically blunted the heart rate
increase during exercise in a concentration dependent manner
[13]. Together, these observations suggest that activation of
presynaptic adenosine A1-receptors by a partial agonist may be a
route to specifically dampen increases in heart rate caused by a
high sympathetic tone.
Because the sympathetic nervous system has a major role in
controlling heart rate, the present study was designed to evaluate
the effect of capadenoson on the sympathetic tone in detail in an
animal model of increased sympathetic activity. An established
model in which an activated sympathetic tone plays a major role is
the SHR strain, which develops hypertensive blood pressure levels
at 5 to 6 weeks of age, followed by cardiac and vascular
hypertrophy and ultimately end-organ failure later in life, if the
hypertension remains untreated [24]. In SHR, an increased NE
overflow from postganglionic nerve terminals has already been
shown before [14,15]. Thus, we chose SHR to study the effects of
the novel adenosine-A1 agonist on the regulation of the
sympathetic tone, and compared them to the effects in Wistar
rats. We hypothesized, that activation of the cardiac adenosine-A1
receptor by capadenoson would reduce stimulation-induced NE
release and consequently blunt the heart rate response during
physical stress particularly in SHR.
Figure 1. Norepinephrine release from isolated rat hearts is modulated by adenosine agonists. A) Mean of absolute NE concentration
released during electrical field stimulation without pharmacologic modulation (Wistar n=18, SHR n=14; p,0.01). B) The effect of capadenoson and
CCPA (capadenoson 6 ? 10
28 M n=6, capadenoson 6 ? 10
27 M n=4, CCPA 10
26 M n=4) in Wistar rats. C) The effect of capadenoson and CCPA
(capadenoson 6 ? 10
28 M n=6, capadenoson 6 ? 10
27 M n=5, CCPA n=7) in SHR. The first stimulation (S1) served as an individual control without
intervention; the second stimulation (S2) was performed after 30 minutes pretreatment with either capadenoson or CCPA. S2/S1 expressed as means
+/2 SEM, * p,0.01 for NE release with pharmacological modulation vs NE release without.
doi:10.1371/journal.pone.0018048.g001
Adenosine A1 Agonism in Cardiac Sympathetic System
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18048As hypothesized, the stress-induced increase of the heart rate
was significantly blunted by capadenoson in SHR. This in vivo
effect of capadenoson was paralleled by a significant reduction of
NE release upon stimulation in isolated hearts of SHR. The effects
of adenosine agonists on norepinephrine release in Wistar rats
have been characterized before. Burgdorf et al.[10] showed that
activation of adenosine-A1 receptors by CCPA or the non-selective
adenosine analogue R(-)N(6)-(2-phenylisopropyl)adenosine (R-
PIA) decrease stimulation-induced NE release by about 50%,
similar to the effect of CCPA we observed in the present study.
Besides an activation of presynaptic A1-receptors, the attenuation
of stimulation-induced norepinephrine release in the presence of
desipramine as an uptake-1 inhibitor may also be explained by an
activated extraneuronal uptake in SHR. [25] However, there is no
evidence that capadenosone activates this extraneuronal uptake,
whereas the presence of A1-receptors presynaptically is well
described. It has been described that the mean concentration of
norepinephrine is higher in the right ventricle and ventricular
Figure 2. Telemetry data from Wistar and SHR during restraint experiment. Shown are the mean heart rate (as percent deviation from
resting normal), and mean arterial pressure the day before, and on the day of the experiment. Blue lines depict vehicle-treated animals, green lines
capadenoson-treated animals (0.15 mg/kg). Shown on the left side are data from Wistar rats (heart rate, above; MAP, below), on the right side the
corresponding values from SHR. Wistar: vehicle and capadenoson each n=20. SHR: vehicle and capadenoson each n=12.
doi:10.1371/journal.pone.0018048.g002
Table 1. Heart rate and blood pressure during physical restraint in Wistar rats and SHR.
Group Heart rate (1/min) MAP (mmHg)
baseline stress
relative
change (%) baseline stress
relative change
(%)
Wistar vehicle 372+/210 432+/281 8 +/239 0 +/221 0 4 +/211 6 +/22
Capadenoson 374+/28 427+/251 5 +/221 0 0 +/211 1 6 +/221 6 +/22
SHR vehicle 324+/211 438+/273 6 +/241 6 4 +/251 8 9 +/231 6 +/212
Capadenoson 328+/26 391+/28* 20+/24* 175+/271 8 9 +/269 +/210
Values are means +/2 SEM. n=20 for Wistar groups, n=12 for SHR groups. MAP mean arterial pressure.
*p=0.001 for comparison of the absolute and relative differences of heart rate during restraint stress in capadenoson-treated vs vehicle-treated SHR.
doi:10.1371/journal.pone.0018048.t001
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However, the functional meaning of the tissue concentration of
norepinephrine is not clear, since the adrenergic activation may be
more dependent on the release and turnover of norepinephrine as
well as on the postsynaptic receptors than on the total amount of
norepinephrine in the heart. Agonists of adenosine A2- and A3-
receptor subtype seem to play no role in the modulation of cardiac
NE release [27]. Adenosine has been shown to exert protective
effects during ischemia and reperfusion through its potential to
limit the release of norepinephrine[10], and is beneficial in
preventing hypertrophic changes under catecholamine stimulation
in vitro [28]. Thus, interventions aimed at a specific modulation of
cardiac NE release would be highly promising in the treatment of
various cardiac diseases, e.g. tachycardia-associated myocardial
ischemia. Compared to a selective b1-blockade, a modulation of
NE release would avoid the negative inotropic effects on the
cardiomyocyte [29,30].
In the present study we could demonstrate that capadenoson
modulates NE release and stress-induced heart rate changes
especially in SHR as a model for a high sympathetic tone, while
heart rate in Wistar rats was not affected by capadenoson. Heart
rate at rest was not affected in either strain. Such a selective
attenuation of sympathetic activity as observed in the present study
might be explained by the partial agonism of capadenoson on the
adenosine-A1 receptor. The lack of effect of a partial agonist, as
opposed to the action of a full agonist, on NE release in Wistar rats
may be explained by the circumstance that the majority of the
presynaptic A1 receptors are already activated by the endogenous
full agonist adenosine, resulting in an effective feedback dampen-
ing of efferent sympathetic activity. By contrast, the presynaptic A1
receptors may be occupied to a much less extent by adenosine in
SHR, which allows for the high sympathetic tone. Under these
circumstances, a partial agonist such as capadenoson would be
capable to activate unoccupied presynaptic adenosine A1 receptors
during states of increased activity (e.g. during restraint stress or
during stimulation in the in vitro experiments) at a significantly
lower concentration than in Wistar rats. Other possible mecha-
nisms underlying the strain-dependent actions of capadenoson on
the stress response and NE release of SHR could be differences in
the density or the molecular architecture of adenosine A1
receptors [31], or higher plasma concentrations of adenosine in
SHR [32]. In a previous study, a similar effect of a different partial
adenosine-A1 agonist, CVT-2759, was noted for the effects of
adrenergic stimulation by isoproterenol in guinea pig myocytes.
Similar to the present study, the partial adenosine A1 agonist had
no effect on basal myocardial function, but attenuated isoproter-
enol-induced arrhythmias, also in a concentration-dependent
manner [33]. Since only female rats were used, the results of the
present study are limited to the female sex. Gender differences
have been well described for the autonomic control of the
Figure 3. Capadenoson is a partial adenosine-A1 receptor agonist. A)Stimulation of [
35S]GTPcS binding to human cortex membranes. Shown
are means +/2 SEM. B) GTP shift assay of the full antagonist DPCPX with and without addition of 1 mM GTP. C) GTP shift assay of the capadenoson,
and D) of CCPA, with and without 1 mM GTP. Shown are means +/2 SEM. Insert in panel A: Chemical structure of capadenoson.
doi:10.1371/journal.pone.0018048.g003
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of capadenosone should taken into account the gender differences
in sympathetic control.
In conclusion, we observed a selective reduction of stimulation-
induced NE release by the partial adenosine A1-receptor agonist
capadenoson in isolated SHR hearts as compared to hearts from
Wistar rats. This effect translates into a blunted heart rate increase
in vivo upon physical restraint in SHR during adenosine A1
agonism, whereas no effect was observed in Wistar rats. These
results suggest that partial adenosine A1 agonism may be a new
way to modulate the sympathetic control of cardiac function.
Supporting Information
Figure S1 Norepinephrine release after control stimu-
lation in the absence of pharmacological intervention.
The second stimulation was performed 30 minutes after the first
one without any pharmacological intervention apart from
desipramine (10
27 M) for inhibition of neuronal uptake of
norepinephrine. Shown is the ratio of norepinephrine overflow
after a first (S1) and second (S2) stimulation. S2/S1 expressed as
means +/2 SEM, p=ns.
(TIF)
Figure S2 Dose-response curves of capadenoson on
mean arterial pressure. A) Dose-response curves of 2 different
concentrations in Wistar rats (n=6 each), and controls. B) Dose-
response curves of 4 different concentrations in SHR (n=12 each),
and controls.
(TIF)
Author Contributions
Conceived and designed the experiments: LBF KCZ KLL HE AK MS.
Performed the experiments: LBF AB HS KCZ BAK RK. Analyzed the
data: LBF HS PL KCZ BAK RK KLL HE AK MS. Contributed
reagents/materials/analysis tools: HS KCZ AK. Wrote the paper: LBF HE
MS.
References
1. Brodde OE, Michel MC (1999) Adrenergic and muscarinic receptors in the
human heart. Pharmacol Rev 51: 651–690.
2. Prichard BN (1987) Bisoprolol: a new beta-adrenoceptor blocking drug. Eur
Heart J 8( Suppl M): 121–129.
3. Richardt G, Waas W, Kranzhofer R, Cheng B, Lohse MJ, et al. (1989)
Interaction between the release of adenosine and noradrenaline during
sympathetic stimulation: a feed-back mechanism in rat heart. J Mol Cell
Cardiol 21: 269–277.
4. Armah BI, Hofferber E, Stenzel W (1988) General pharmacology of the novel
centrally acting antihypertensive agent moxonidine. Arzneimittelforschung 38:
1426–1434.
5. Head GA, Burke SL, Chan CK (1997) Central imidazoline receptors and
centrally acting anti-hypertensive agents. Clin Exp Hypertens 19: 591–605.
6. Ernsberger P, Haxhiu MA (1997) The I1-imidazoline-binding site is a functional
receptor mediating vasodepression via the ventral medulla. Am J Physiol 273:
R1572–1579.
7. Guyenet PG (1997) Is the hypotensive effect of clonidine and related drugs due
to imidazoline binding sites? Am J Physiol 273: R1580–1584.
8. Szabo B (2002) Imidazoline antihypertensive drugs: a critical review on their
mechanism of action. Pharmacol Ther 93: 1–35.
9. Hattori Y, Kanno M (1998) Role of alpha1-adrenoceptor subtypes in production
of the positive inotropic effects in mammalian myocardium: implications for the
alpha1-adrenoceptor subtype distribution. Life Sci 62: 1449–1453.
10. Burgdorf C, Richardt D, Kurz T, Seyfarth M, Jain D, et al. (2001) Adenosine
inhibits norepinephrine release in the postischemic rat heart: the mechanism of
neuronal stunning. Cardiovasc Res 49: 713–720.
11. Seyfarth M, Feng Y, Hagl S, Sebening F, Richardt G, et al. (1993) Effect of
myocardial ischemia on stimulation-evoked noradrenaline release. Modulated
neurotransmission in rat, guinea pig, and human cardiac tissue. Circ Res 73:
496–502.
12. Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential
therapeutic applications. Expert Opin Investig Drugs 17: 1901–1910.
13. Tendera M, Sosnowski M, Gaszewska-Zurek E, Parma Z, Neuser D, et al.
(2007) The oral adenosine A1 receptor agonist, BAY68-4986, reduces heart rate
at peak exercise in patients with chronic stable angina. J Am Coll Cardiol 49: A
232.
14. Zsoter TT, Wolchinsky C, Lawrin M, Sirko S (1982) Norepinephrine release in
arteries of spontaneously hypertensive rats. Clin Exp Hypertens A 4: 431–444.
15. Zugck C, Lossnitzer D, Backs J, Kristen A, Kinscherf R, et al. (2003) Increased
cardiac norepinephrine release in spontaneously hypertensive rats: role of
presynaptic alpha-2A adrenoceptors. J Hypertens 21: 1363–1369.
16. Nell P, Albrecht-Ku ¨pper B (2009) The Adenosine A1 Receptor and its Ligands.
In: Lawton G, Witty DR, eds. Progress in Medicinal Chemistry: Elsevier. pp
164–201.
17. Elworthy PM, Hitchcock ER (1986) Estimation of plasma catecholamines by
high-performance liquid chromatography with electrochemical detection in
patients with subarachnoid haemorrhage. J Chromatogr 380: 33–41.
18. McDougall SJ, Paull JR, Widdop RE, Lawrence AJ (2000) Restraint stress :
differential cardiovascular responses in Wistar-Kyoto and spontaneously
hypertensive rats. Hypertension 35: 126–129.
19. Lorenzen A, Fuss M, Vogt H, Schwabe U (1993) Measurement of guanine
nucleotide-binding protein activation by A1 adenosine receptor agonists in
bovine brain membranes: stimulation of guanosine-59-O-(3-[35S]thio)tripho-
sphate binding. Mol Pharmacol 44: 115–123.
20. Lorenzen A, Guerra L, Vogt H, Schwabe U (1996) Interaction of full and partial
agonists of the A1 adenosine receptor with receptor/G protein complexes in rat
brain membranes. Mol Pharmacol 49: 915–926.
21. Lohse MJ, Lenschow V, Schwabe U (1984) Interaction of barbiturates with
adenosine receptors in rat brain. Naunyn Schmiedebergs Arch Pharmacol 326:
69–74.
22. Lohse MJ, Klotz KN, Lindenborn-Fotinos J, Reddington M, Schwabe U, et al.
(1987) 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)–a selective high affinity
antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch
Pharmacol 336: 204–210.
23. Van der Wenden EM, Hartog-Witte HR, Roelen HC, von Frijtag Drabbe
Kunzel JK, Pirovano IM, et al. (1995) 8-substituted adenosine and theophylline-
7-riboside analogues as potential partial agonists for the adenosine A1 receptor.
Eur J Pharmacol 290: 189–199.
24. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, et al. (1995)
Myocardial fibrosis and stiffness with hypertrophy and heart failure in the
spontaneously hypertensive rat. Circulation 91: 161–170.
25. Grundemann D, Koschker AC, Haag C, Honold C, Zimmermann T, et al.
(2002) Activation of the extraneuronal monoamine transporter (EMT) from rat
expressed in 293 cells. Br J Pharmacol 137: 910–918.
26. Tsuboi H, Ohno O, Ogawa K, Ito T, Hashimoto H, et al. (1987) Acetylcholine
and norepinephrine concentrations in the heart of spontaneously hypertensive
rats: a parasympathetic role in hypertension. J Hypertens 5: 323–330.
27. Lorbar M, Chung ES, Nabi A, Skalova K, Fenton RA, et al. (2004) Receptors
subtypes involved in adenosine-mediated modulation of norepinephrine release
from cardiac nerve terminals. Can J Physiol Pharmacol 82: 1026–1031.
28. Gan XT, Rajapurohitam V, Haist JV, Chidiac P, Cook MA, et al. (2005)
Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation
of multiple adenosine receptor subtypes. J Pharmacol Exp Ther 312: 27–34.
29. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, et al. (1987) Role of
neurohormonal mechanisms in determining survival in patients with severe
chronic heart failure. Circulation 75: IV80–92.
30. Persson H, Andreasson K, Kahan T, Eriksson SV, Tidgren B, et al. (2002)
Neurohormonal activation in heart failure after acute myocardial infarction
treated with beta-receptor antagonists. Eur J Heart Fail 4: 73–82.
31. Kobayashi S, Umemura S, Toya Y, Hirawa N, Hayashi S, et al. (1996)
Adenosine A1 receptor and its gene expression in ventricles from spontaneously
hypertensive rats. Am J Physiol 271: R704–709.
32. Yamada K, Goto A, Ishii M, Yoshioka M, Matsuoka H, et al. (1992) Plasma
adenosine concentrations are elevated in conscious spontaneously hypertensive
rats. Clin Exp Pharmacol Physiol 19: 563–567.
33. Song Y, Wu L, Shryock JC, Belardinelli L (2002) Selective attenuation of
isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1
receptor. Circulation 105: 118–123.
34. Dart AM, Du XJ, Kingwell BA (2002) Gender, sex hormones and autonomic
nervous control of the cardiovascular system. Cardiovasc Res 53: 678–687.
Adenosine A1 Agonism in Cardiac Sympathetic System
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e18048